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 ABSTRACT 
 
CONCURRENT CHEMO RADIATION WITH CISPLATIN AND 
BLEOMYCIN VERSUS CISPLATIN ALONE IN LOCALLY 
ADVANCED SQUAMOUS CELL CARCINOMA OF ORAL 
CAVITY: A RETROSPECTIVE STUDY 
Dr.Anbarasi.K, Cancer institute(WIA) 
 
Background: 
 
Oral cavity cancer constitutes two thirds of locally advanced head 
and neck cancer in India and majority presents in advanced stage. 
Despite aggressive treatment disease outcome is poor. The aim of this 
study is to compare concurrent chemo radiation with cisplatin and 
bleomycin versus concurrent chemo radiation with cisplatin alone in 
locally advanced oral cavity cancer.  
 
Materials and methods: 
 
Patients with locally advanced squamous cell carcinoma of oral 
cavity cancers registered at cancer institute from 2009 – 2011 were 
included in the study. Patients who were either taken up for initial 
surgery or treated with radiation therapy alone were excluded from 
study. Of 515 patients treated with concurrent chemo radiation, 112 
patients were treated with three weekly cisplatin along with biweekly 
bleomycin and 104 patients were treated with 3 weekly cisplatin alone  
concurrent with radiation therapy. 
 
Results: 
 
Among the patient treated with three weekly cisplatin and 
biweekly bleomycin there is increased two year disease free survival 
(45.5% versus 35.6%) and two year overall survival(60% versus 
45.2%)on comparison with patients treated with three weekly cisplatin 
alone.(P <0.05). Three weekly cisplatin alone has lesser incidence of 
grade III mucositis, but comparable treatment breaks haematological 
toxicity, vomiting, treatment response when compared to three weekly 
cisplatin along with biweekly bleomycin. 
 
Conclusion: 
The addition bleomycin to cisplatin concurrently with radiation 
therapy increases disease free survival and overall survival, with 
manageable toxicity. 
 
Key words:  
 
Cisplatin, bleomycin, oral cavity cancer, survival, radiation 
therapy. 
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I.INTRODUCTION 
 
I.1 ANATOMY: 
 
 The oral cavity extends from the vermilion border of lips to the 
oropharyngeal isthmus. It is bounded by the hard and soft palate junction  
superiorly, the floor of mouth inferiorly, the anterior tonsillar pillar laterally and by 
circumvallate papillae posteriorly. The entire oral cavity is lined with mucous 
membrane tissue. The oral cavity divided into various subsites including lips, 
anterior two third of tongue, floor of mouth, buccal mucosa, gingivum, retro molar 
 trigone and hard palate.  
 
 
 
Fig 1: Anatomy of oral cavity a)lateral view b)anterior view 
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LIP: 
 
 The lips are divided into two parts, the upper lip and the lower lip. The lips 
are the transition point between facial skin and mucosal lining of the mouth and the 
meeting point is called vermilion border. The lips are mainly composed of 
orbicularis oris muscle. Both upper and lower lips are attached to gingival by labia 
frenula which forms by raised folds of mucous membrane. The arterial supply is 
from branches of facial artery namely superior and inferior labial arteries.The 
motor supplies are buccal and mandibular branches of facial nerve. The sensory 
innervation to upper   and lower are the infraorbital nerve and the mental nerve 
respectively. The lips drain primarily into submental nodes, parotid nodes, 
submandibular nodes which in turn drain secondarily into jugulodigastric 
nodes.vascular membrane.  
 
TONGUE: 
 
 The anterior two third of tongue is mobile and considered as a part of the 
oral cavity. The sulcus terminalis divides the anterior two third (oral part) of 
tongue from posterior one third (pharyngeal part). The oral tongue extends 
anteriorly from line of circumvallate papillae to undersurface of the tongue at the 
junction of the floor of mouth. The ventral surface of the tongue attached to floor 
of mouth by lingulam frenulum. The oral tongue has four areas: the tip, dorsal 
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surface, lateral borders and the ventral surface. The oral tongue is divided into two 
halves by fibrous septum.    
 
 
 
Fig 2: Coronal section of anterior tongue showing muscles of tongue and 
relationship 
 
Each halves consists of four extrinsic muscles and four intrinsic muscles. 
The extrinsic muscles arises from the bone and onserts into tongue. Extrinsic 
muscles are genioglossus, hyoglossus, styloglossus and palatoglossus and all helps 
in altering tongue position and allows side to side movements, protrusion, 
retraction, elevation and depression. The intrinsic muscles originate in tongue and 
inserted within tongue. Intrinsic muscles are superior longitudinal muscle, inferior 
longitudinal muscle, verticalis muscle and transverses muscle and helps in altering 
shape of tongue and important for fine motions during articulation and bolus 
preparation.  
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 The blood supply is primarily by lingual artery, a third branch of external 
carotid artery & its branches and drains into two lingual veins accompanying 
lingual artery and finally into internal jugular vein.  
 
 
 
Fig: 3 Vascular and nerve supply of tongue 
 
  The motor supply of anterior two third of tongue is by hypoglossal nerve. 
The general sensory innervations and special sensory (taste) innervations to 
anterior two third of nerve are lingual nerve and chorda tympanic branch of facial  
nerve respectively.  
 
 The lymphatic drainage of oral tongue has three routes. The lymphatics from 
tip of the tongue and frenulum drain into submental nodes.  Lymphatics from the 
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lateral part drain into submandibular nodes which in turn drains into deep cervical 
lymphnodes. The lymphatics from central tongue drain directly into deep cervical  
lymphnodes of either side.  
 
 
Fig:4 Lymphatic drainage of tongue 
 
 
FLOOR OF MOUTH: 
 
 The floor of mouth is a semilunar space overlying hyoglossus and 
mylohyoid extending from inner surface of mandibular alveolar ridge to the ventral 
surface of the tongue. Posteriorly it extends till base of the anterior tonsillar pillar. 
The muscular sling formed by mylohyoid, geniohyoid and genioglossus supports 
the floor of mouth. The floor of mouth is divided into two halves by frenulum and 
contains ostia of sumandibular, sublingual and minor salivary glands. The blood 
supply is by sublingual artery and drains into sublingual veins and form deep 
lingual veins. The general sensory innervation is by lingular branch of mandibular 
nerve. Lymphatic drainage of floor of mouth is divided into anterior and posterior 
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complexes. The anterior complex drains anterior part of floor of mouth into 
submandibular nodes mainly and submental nodes. The posterior complex drains 
posterior part of floor of mouth into juguloomohyoid nodes. Bilateral drain occurs 
commonly.  
 
GINGIVA: 
 
 The gingiva is composed of fibrous tissue and is mucosal lined extensions 
from floor of mouth and roof of oral cavity which contain the teeth. There are three 
types of gingiva: 
 
1) Free or unattached or marginal gingiva- loosely tissue continous with lining  
of oral cavity.  
2) Interdental gingival- part of gingiva that fills the space between the teeth. 
3) Attached gingival- closely attached to periosteum of alveolar processes of 
maxilla and mandible.      
 
The blood supply of the gingiva is by branches of superior and inferior alveolar 
artery. The gingiva receives sensory innervations fom mandibular and maxillary 
branch of trigerminal nerve. The gingiva drains into submandibular nodes mainly 
and submental nodes.  
 
 
 
7 
 
BUCCAL MUCOSA: 
 
 The cheeks form the lateral wall of the oral cavity. The buccal mucosa 
formed by mucosal lining of cheek and lips.  The external surface of cheek is 
covered by skin. Buccinator muscle and buccal pad of covering it gives the 
rounded contour of cheek. The blood supply is by buccal branch of maxillary 
artery and drains into pterigoid plexus of veins and finally into internal jugular 
vein.  The sensory innervation is by maxillary and mandibular branch of 
trigerminal nerve and motor supply is by facial nerve. The inferior and medialparts 
of cheek drains into submandibular nodes and superior and lateral parts drain into 
preauricular nodes.  
 
RETROMOLAR TRIGONE: 
 
 The retromolar trigone is the small triangular area posterior to the third 
molar. The apex of triangle is formed by maxillary tuberosity and base of the 
triangle by the posterior third molar. The mucosa attached to hamulus of the 
medial pterygoid of sphenoid bone. The sensory innervation is by branches of 
lesser palatine nerve and glossopharyngeal nerve. The blood supply is by tonsillar 
and ascending palatine branches of facial artery and drains through tonsillar bed to 
pharyngeal plexus and to common facial vein. The lypmph from retromolar trigone 
drains into upper deep jugular nodes mainly and lateral pharyngeal nodes. 
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HARD PALATE: 
 
 The hard palate is a semilunar area forms the roof of oral cavity and floor of 
The nasal cavity. It extends from the superior alveolar ridge to the posterior edge 
of the palatine bone. The hard palate is formed by palatine process of maxilla and 
horizontal plates of palatine bone. The mucosa of the hard palate is closely 
adherent to the overlying periosteum. The blood supply is by greater palatine 
arteries and veins. The anterior part of hard palate is by nasopalatine nerve and 
ucous membrane and posterior parts innervated by greater palatine nerve. It drains 
into submandibular nodes or directly into superior deep cervical nodes.  
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I.2. OVERVIEW OF ORAL CAVITY CANCER 
 
 
EPIDEMIOLOGY: 
 The oral cavity cancer is the sixth commonest cancer reported in the world 
with an annual incidence of over 300,000 cases. More than 62% of these cases are 
from developing countries. The age adjusted standard rates in India is over 20 per 
100,000 populations whereas in United States it is 10 per 100,000 and lowest in 
Japan is 0.2 per 100,000.  It constitutes 30% of the cancer burden in India. Tongue 
and cheek cancer are the most common sites and majority of them present in 
locally advanced stage.  
 
Fig:5-Age standardized incidence rates of oral cavity cancers by sex and 
world area 
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 It is the most common cancer in males with an annual incidence of 45,455 
and fourth common cancer in females with an incidence of  24,375.  
 
RISK FACTORS: 
 
 Chewing tobacco products, smoking, alcohol and viral infection are the 
commonest risk factors of oral cavity cancers. In India chewing betal nut mixed 
with tobacco is the major cause of oral cavity cancer. Smoking is an independent 
risk factor of oral cavity cancer patients. Alcohol and smoking has synergistic 
action on carcinogenesis and alcohol acts an independent risk factor of oral cavity 
cancer. Herpes simplex virus acts as a cocarcinogen with tobacco and UV light. 
Around 50% of cases of oral cavity cancer has HPV infection especially HPV6 and 
HPV16. Ultraviolet light is a risk factors for carcinoma of lip. Other risk factors 
like poor oral hygiene, nutritional hygiene, continuous irritation of oral cavity also 
cause oral cavity cancer. 
 
HABIT RELATIVE RISK % 
None 1% 
Betal nut chewing 4% 
Smoking only 3-6% 
Betal chewing+tobacco 8-15% 
Betal chewing+smoking 4-25% 
Betal+tobacco+smoking 20% 
 
Table 1-Relative risk of oral cavity cancers according to habits of the patients. 
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PREMALIGNANT LESIONS: 
 
LEUKOLPLAKIA: 
 
 Leukoplakia is the most common premalignant lesion of oral cavity. 
Clinically it appears as chronic white verrucous plaque, nodular, with ulceration or 
erosion. It occurs anywhere in the oral cavity. 1-18% of leukoplakia develops into 
oral cavity cancer. 
 
ERYTHROPLAKIA: 
 
 Erythroplakia has high chance of development of oral cavity cancer upto 
51%.Clinically it appears as a chronic, red non inflammatory plaque on mucosal 
surface of oral cavity. As it has higher risk of malignant transformation it should be 
excised surgically. 
 
SUBMUCOUS FIBROSIS: 
 
 Submucous fibrosis occurs in people who chew tobacco along with betal nut 
and lime. Clinically it appears as generalized white discolouration of oral mucosa 
with progressive fibrosis, painful muscular atrophy and restrictive fibrotic bands. If 
it is severe it leads to trismus, dysphagia and xerostomia. 5-10% chance of 
malignant transformation present. 
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PATHOLOGY: 
 
 Ninety percent of oral cavity cancers are squamous cell carcinoma. 
Remaining ten percent of the patients have non squamous histology like adenoid 
cystic carcinoma, adenocarcinoma, ameloblastoma, lymphoma, sarcoma and 
melanoma. 
 
STAGING AND GROUPING SYSTEM: 
 
PRIMARY TUMOR (T): 
 
 
 
 
 
             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tx Primary tumor cannot be assessed 
To  No evidence of primary tumor 
Tis Carcinoma in situ 
T1 Tumor 2cm or less in greatest dimension 
T2 Tumor more than 2cm but not more than 4cm in 
greatest dimension 
T3 Tumor more than 4cm in greatest dimension 
T4a(lip) Tumor invades through cortical bone , inferior 
alveolar nerve, floor of mouth or skin of face. 
T4a(oral 
cavity) 
Tumor invades through cortical bone into deep 
(extrinsic) muscle of tongue ( genioglossus, 
hyoglossus, palatoglosus and styloglossus), maxillary 
sinus or skin of face. 
T4b Tumor involves masticator space, pterygoid plate ,or 
skull base and/or encases internal carotid artery. 
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REGIONAL LYMPHNODES (N): 
 
 
 
 
 
 
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISTANT METASTASIS(M): 
 
 
 
                       
  
Nx  Regional lymph nodes cannot be assessed. 
No  No regional lymph nodes. 
N1 Metastasis in a single ipsilateral lymph node less 
than or equal to 3cm in greatest dimension. 
N2 Metastases in a single ipsilateral lymph node >3 
cm, but <6 cm in greatest dimension; or in 
multiple lymph nodes none >6 cm in greatest 
dimension; or in bilateral or contralateral lymph 
nodes 
N2a Metastases in a single ipsilateral lymph node >3 
cm, but not more than 6 cm in greatest dimension 
N2b Metastases in multiple lymph nodes none more 
than 6 cm in greatest dimension 
N2c Metastases in bilateral or contralateral lymph 
nodes, none 6 cm in greatest dimension 
N3 Metastases in a lymph node >6 cm in greatest 
dimension 
Mx Distant metastases cannot be assessed. 
Mo  No distant metastases. 
M1 Distant metastases. 
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STAGE GROUPING: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
TREATMENT: 
 
 The treatment approaches of the carcinoma of oral cavity include surgery, 
radiation therapy, combination of surgery and radiation therapy and concurrent 
chemo radiation therapy. For patients with stage I and II either modality surgery or 
STAGE T N M 
Stage 0 Tis N0 M0 
Stage I T1 N0 M0 
Stage II T2 N0 M0 
Stage III T3 
 
T1-T3  
 
 
N0 
 
N1 
M0 
 
M0 
Stage IV A T4a 
 
 
T1- T3 
 
 
N0- N2 
 
 
N2  
M0 
 
 
M0 
Stage IV B T4b 
 
Any T 
Any N 
 
N3 
 
M0 
 
M0 
Stage IV C Any T Any N M1 
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radiation has high chance of cure. Surgery is the preferred modality of treatment of 
oral cavity cancer among head and neck cancers because 
 
 Oral cavity carcinomas can be approached easily by surgery as it is easily 
accessible and without major surgical dissection. 
 
 For early cancers organ function can be well preserved even after excision. 
The maxillodental bony structures interfere with the dose received by tumor 
and at radical dose of radiation late complications like osteoradionecrosis 
require major surgery. 
 
 Most of the oral cavity cancers are well differentiated and less sensitive to 
radiation therapy and chemotherapy.  
 
 Histology other than squamous cell carcinoma like sarcoma and minor 
salivary gland tumor are less responded to radiation therapy. 
 
 Due to involuntary mobility of tongue and air–tissue interfaces within mouth 
more acute toxicities during radiation delays the treatment.When the oral 
cavity carcinomas can be resectable without compromising functional loss 
surgery is the preferred treatment.  
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In locally advanced carcinoma concurrent chemo radiation is the alternate 
treatment of choice. The small tumors can effectively treated by brachytherapy and 
the result is same as that of surgery. The advanced cancers generally require 
combined modality approach. The treatment of oral cavity cancers is highly 
individualized and depends on stage of disease, subsite involved, and physician 
preferences and varies from institution to institutions. There are no definite 
guidelines for the treatment of oral cavity cancers. Patients who are unable to 
withstand major surgery can be treated with radiation therapy and concurrent 
chemotherapy. The choice of treatment depends on the cosmetic changes, 
complications and functional consequences that the treatment is expected to cause. 
The overview of treatment option by tumor site, local control and five year 
survival rates by tumor site and disease stage summarized in the following tables. 
 
 
 
Table 2- shows overview of treatment options of oral cavity cancers by tumor 
site. 
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Table 3-Local control rates and 5 year survival rates by tumor site and stage. 
 
 
SURGERY ALONE: 
 
 Surgical resection of primary is the treatment for early T1 lesions and T2 
lesions of cheek, tongue, lip and floor of mouth followed by supraomohyoid 
dissection or extended dissection. 
 
RADIOTHERAPY ALONE: 
 
 Radiotherapy alone can be given by brachytherapy or external beam 
radiation for T1 and T2 lesions of lip, tongue, cheek and floor of mouth. Patient 
who are unfit for surgery and chemotherapy can also treated with radiation therapy 
alone. 
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COMBINED RADIATION THERAPY AND SURGERY: 
 
 Combined modality treatment achieves optimal results in locally advanced 
carcinoma of oral cavity. Initial surgery followed by radiation therapy is 
recommended in 
 
 Large primary lesion 
 Deeply infiltrative 
 Necrotic 
 Bone invasion 
 Deep muscle invasion 
 Cervical lymph node metastasis 
 Soft tissue involvement of neck 
 
The aims of postoperative radiation are 
 
 To prevent and reduce local recurrence in case large tumors 
 To prevent regional recurrence when there is multiple lymph node 
metastasis or soft tissue invasion in neck. 
 To control occult disease those are not dissected surgically. 
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Postoperative radiation therapy is usually given to surgical bed of primary 
and neck and dose of 60 – 66Gy delivered in 1.8Gy – 2Gy per fraction daily and 
five fractions a week. Postoperative radiation starts after complete wound healing 
usually 2 to 3 weeks after surgery. 
 
COMBINED RADIATION THERAPY AND CHEMOTHERAPY AND 
SURGERY: 
 
Surgery followed by chemotherapy and radiation therapy is indicated in 
 
 Positive margins or gross residual disease 
 Extra capsular extension. 
 
RTOG 9501 and EORTC 22931 are the two landmark studies demonstrated 
better local control and survival in patients with positive margins and extra 
capsular extension when treated with concurrent chemo radiation compared to 
radiation alone. 
 
COMBINED CHEMOTHERAPY AND RADIATION THERAPY FOR 
LOCALLY ADVANCED DISEASE: 
 
Though chemotherapy for oral cavity cancers started in earlier 1960’s, it was 
given only in recurrent and metastatic conditions. Later chemotherapy was given 
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concurrently with radiation in locally advanced oral cavity cancer in order to 
improved cosmesis, function, local control and overall survival. Several meta-
analyses compared concurred chemo radiation with radiation alone in locally 
advanced head and neck cancers and it was found that there is absolute benefit in 
overall survival by 5-8%. However the number of patients included in oral cavity 
cancers is small in many randomized studies. In 1961 Lo et al in a randomized 
study found that there is increased in over survival of oral cavity cancer patients 
who received 5-Fluorouracil concurrently with radiation compared to radiation 
alone.  Other studies did not find the significant benefit in overall survival in oral 
cavity cancers when treated with single agent chemotherapy concurrent with 
radiation. Whereas multiagent chemotherapy is given in oral cavity cancers shows 
improved local control and overall survival when given concurrently with radiation 
therapy. The chemotherapeutic agents used concurrently with radiation were 
cisplatin, paclitaxel, 5-fluorouracil and bleomycin. 
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I.3.CONCEPT OF CONCURRENT CHEMO RADIATION. 
 
INTRODUCTION: 
 
 The combined modality approach in cancer treatment is now acknowledged 
as better treatment in head and neck cancer as it increases the overall survival and 
better organ conservation. Chemotherapy is given as neoadjuvant, concurrent or 
adjuvant to radiation therapy. 
 
 Chemotherapy is given before radiation to reduce the size of tumor and so 
field of radiation.  
 
 Chemotherapy also given along with radiation considering it may sensitize 
cells to radiation and to reduce the subclinical disease at distant sites.  
 
 Chemotherapy delivered after radiotherapy to reduce distant subclinical 
disease and to reduce patient’s toxicity.     
 
In late 1950s the fact that the anticancer drugs could affect the responses to 
radiation was first appreciated during the use of dactinomycin D in the clinical 
evaluation of wilm’s tumor where there is increased radiation reaction in normal 
tissue in addition to increased damage to the tumor.  These lead to systematic study 
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of interactions of antitumour drugs and radiation responses on normal tissue. The 
review of results of these studies showed that there enhanced response to radiation 
of normal tissue when anticancer drugs given concurrently with radiation.  In 1966 
McGrath and Williams proved that ionizing radiation produce damage in DNA. It 
is well known that anticancer drugs cause DNA damage. When these two interacts 
it is expected to cause more DNA damage. 
 
The rationales of combining chemotherapeutic drugs with radiation therapy are   
 
 Organ preservation resulting in improved cosmesis and function,  
 
 Acts as radio sensitizer , improving local control and survival,  
 
 Act systemically and eradicate distant micro metastases. 
 
 
THERAPEUTIC RATIO: 
 
  Both radiation therapy and chemotherapeutic agents are cytotoxic to tumor 
and normal tissue cells. To be therapeutically beneficial radiotherapy, 
chemotherapy or both should increase tumor control and lesser damage to normal 
cells. But there is lack of specificity and is a major limitation in their use when 
applied either as individual treatments or in combination. Radiation inflicts damage 
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to tumor and normal tissues in the radiation treatment field.Chemotherapy systemic 
action can affect any tissue in the body.  
 
So toxicity is often increased when two modalities are combined.  In 
general, both the antitumor efficacy and the severity of normal tissue toxicity 
produced by either radiation or drugs are increased as their dose is increased. This 
dose-effect relationship is sigmoidal and enables estimation of the therapeutic 
index (ratio), which is defined  as the ratio between the doses (radiation, drug) that 
produce the same level (probability) of antitumor efficacy and normal tissue 
damage. To be therapeutically beneficial, the therapeutic ratio must be positive 
(>1); that is, individual agents or their combination must be more effective against 
tumors than normal tissues.  
 
 In 1979 Steel and Peckham(1) explained the theoretical types of interaction 
of cytotoxic chemotherapy and radiotherapy that improves therapeutic ratio. 
 
1) Spatial cooperation 
2) Independent toxicity 
3) Enhancement of tumor response 
4) Protection of normal tissues. 
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SPATIAL COOPERATION: 
 
 Spatial cooperation was the initial rationale of combining chemotherapy and 
radiotherapy in which radiotherapy acts locoregionally and chemotherapy acts 
against micro metastases outside radiation field and both the action are 
independent of each other.  This cooperation requires the drug which would not 
increase normal tissue toxicity as an additive effect and it should be used with 
effective doses of both modalities.For example in hematological malignancies like 
leukemia radiation therapy is used to treat sanctuary site like brain and 
chemotherapy is used systemically. 
 
 
 
Fig 6 shows interaction of chemotherapy and radiation therapy 
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INDEPENDENT TOXICITY: 
 
 Toxicity to normal tissues is the major dose limiting factor for both radiation 
therapy and chemotherapy. Independent toxicity is an important rationale to 
increase the therapeutic ratio. If radiotherapy and chemotherapy given at full dose 
the response to tumor (cell kill) is more than the treatment with single modality 
alone even in the absence of interaction between chemotherapy and radiation 
therapy. To achieve this, the chemotherapeutic drug and radiation should not have 
overlapping toxicities. For example- In treatment of early stage hodgkins 
lymphoma combination of chemotherapy and radiation (mantle field) is highly 
effective for long term cure with increased long term effects. Now combing 
different chemotherapy agents the radiation field (involved field) and dose is 
reduced to get same efficacy. Retaining antitumor efficacy and minimizing normal 
tissue toxicity requires knowledge of individual drug toxicity, mechanism of action 
and pharmacokinetics of individual drug to combine with radiation. 
 
ENHANCEMENT OF TUMOR RESPONSE: 
 
 It refers to the capacity of chemotherapy which may enhance tumor damage 
when interacts with radiation or sometimes radiation make cells sensitive to 
chemotherapy probably by interacting with chemotherapy at molecular, cellular , 
metabolic or pathophysiologic level. This interaction can also cause additional 
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damage to normal tissue apart from enhancement of tumor damage. Therapeutic 
gain can be achieved only when enhancement caused by interaction between 
chemotherapy and radiation therapy is selective to tumor rather than critical normal 
tissues. 
   
PROTECTION OF NORMAL TISSUE: 
 
 This strategy is to increase tolerance to normal tissues so that higher doses of 
radiation therapy can be safely delivered to the tumor. In vivo testing showed that 
amifostine protect the salivary gland function during head and neck radiotherapy.  
The increased toxicity to normal tissue with radiation in setting of concurrent 
chemo radiation can be achieved by advances in radiotherapy treatment like 
conformal planning (3DCRT, IMRT), use of protons and use of radioprotectants 
like amifostine. 
 
MECHANISMS OF CHEMOTHERAPY AND RADIOTHERAPY 
INTERACTIONS: 
 There are seven possible major interactions between radiotherapy and 
chemotherapy at cellular and molecular level. Usually more than one type of 
interactions occurs during concurrent chemo radiation and depends upon the type 
of chemotherapy used. 
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1 INITIAL RADIATION DAMAGE: 
 
DNA is the critical target for both radiation therapy and chemotherapy. 
Radiation induces lesions in DNA like base damage, single strand breaks, double 
strand breaks , alkali labile sites and DNA-DNA cross links. All these lesions 
except double strand breaks can be easily repaired. Double strand break is either 
misrepaired or unrepaired leading to chromosomal aberrations and finally leads to 
cell death.  When chemotherapy (e.g. - halogenated pyramidines) given 
concurrently it become incorporated into DNA and make more susceptible for 
radiation damage. Certain drugs (e.g.-cisplatin) interfere in cellular repair 
mechanism and enhance the sensitivity of tumor cells to radiation. Cisplatin 
integrates with DNA in close proximity to SSB caused by radiation and makes 
difficult to repair the DNA. 
 
 
Fig 7 shows mechanism of interaction of cisplatin and radiation on DNA. 
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2 INHIBITION OF DNA REPAIR PROCESS: 
 
 After radiation DNA damage repair will occur. Chemotherapy cause 
inhibition of post radiation induced damage repair process. As DNA synthesis and 
DNA repair process have common pathways chemotherapy which inhibits DNA 
synthesis will inhibit DNA repair. In patients chemotherapeutic agents which alter 
the nucleoside or nucleotide mechanism will inhibit the repair of radiation induced 
DNA lesions and acts as potent radiosensitizer. E.g. Nucleoside analogs, thymidine 
analogs,halogenated pyramidines, cisplatin etc. 
 
3 CELL CYCLE INTERFERENCE: 
 
 In 1963 Terasima and Tolmach first reported the radiation response is 
influenced by cell cycle.  The cells in S phase are most resistant and cells in G2 & 
M phase are most sensitive to radiation. Chemotherapeutic agents are used to 
overcome this variation in radiosenstivity when given along with radiation. The 
drug whichselectively destroys cells in S phase or drugs which accumulate cells in  
G2 & M phase is used. 
 
E.g.  
 1)  Taxanes inhibit tubulin depolymerisation and cause cells to arrest in  
  radiosensitive G2-M phase of cell cycle. 
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 2) Nucleoside analogs like fludarabine incorporates with cells at S phase  
 and cause cell damage at S phase. This also causes accumulation of   
 cells in radiosensitive G2M phase of cell cycle. 
 
 
 
Table 4 shows different mechanism of interaction oh chemotherapy and 
radiation therapy. 
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4 EFFECT ON HYPOXIA: 
 
 It is well known that oxygen influence on sensitivity of cells to radiation. 
Hypoxic cells have shown increased resistance to radiation. Chemotherapy can 
abolish these hypoxic cells by multiple mechanisms. 
 
1) Destroying tumor in oxygenated areas so that reoxygenation occurs. (E.g. 
paclitaxel, EGFR inhibitors). 
2) Selectively destroying hypoxic cells. (e.g. Mitomycin C, Tirapazamine) 
3) Radiosenstizing hypoxic cells. (e.g. Misonidazole) 
 
5 PREVENTING REPOPULATION: 
 
 There is a homeostasis between cell production and cell loss in normal 
tissues. In tumor tissue there is increased cell proliferation. Chemotherapy and 
radiotherapy causes increased cell loss and there is compensatory cell repopulation. 
Fractionated radiation therapy reduces repopulation. When chemotherapy is given 
along with radiation therapy repopulation is reduced by decreased cell 
proliferation. Example: Chemotherapy agents that acts on S phase (e.g. 5-
flurouracil) and agents that inhibit proliferation and their pathways (e.g. EGFR 
inhibitors) were good in reducing tumor repopulation . In addition it also inhibits 
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normal tissue regeneration which adds to treatment toxicity and it is the major 
limitation for concurrent chemo radiation. 
 
6 INHIBITION OF POOR SURVIVAL MARKERS: 
 
 Agents that block signaling pathway like EGFR inhibitors and 
antiangiogenic agents prevents radioresistance and aggressive tumor biology as it 
is the major pathway for both. 
 
7 HYPERRADIATION SENSITIVITY: 
 
 Some cancers are resistant to standard concurrent chemo radiation. They will 
respond to alterations in radiation fractionation. This phenomenon is termed 
hyperradiation sensitivity. It is observed at radiation doses greater than 1 Gy. This 
radioresistance can overcome by paclitaxel, docetaxel , low dose radiation 
preclinically. This mechanism is currently investigated in clinical trial. 
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CHEMOTHERAPEUTIC AGENTS USED CONCURRENTLY WITH 
RADIATION IN HEAD AND NECK CANCERS: 
 
 The chemotherapeutic agents can be used in chemo radiotherapy as single 
agent or multi agents. As the number of agents increases there is increased 
radiosensitization and with increased toxicity.  
 
 
Table 5 Oveview of single agent chemoradiotherapy trials in head and neck 
cancers. 
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-  
 
Table 6: Ovetview of multi-agent chemoradiotherapy trials in head and neck 
cancers. 
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TOXICITIES OF CONCURRENT CHEMO RADIATION: 
 
RTOG SCORING CRITERIA: 
 
 Grade 
 (0) 
Grade  
(1) 
Grade  
(2) 
Grade 
 (3) 
Grade 
 (4) 
 
  SKIN 
No 
difference 
from 
baseline 
Faint or 
Follicular, or 
dull 
erythema/ 
epilation/dry 
desquamatio
n/ impaired 
sweating 
Tender or 
bright 
erythema, 
patchy moist 
desquamation/ 
moderate 
oedema 
Confluent, 
moist 
desquamation 
other than 
skin folds, 
pitting 
oedema 
Ulceration
, 
haemorrha
ge, 
necrosis 
MUCOUS  
MEMBRA
NE 
No 
difference 
from 
baseline 
Injection/ 
may 
experience 
mild pain 
not requiring 
analgesic 
Patchy 
mucositis 
leading to  
inflammatory 
serosanguinitis 
discharge/ 
moderate pain 
requiring 
analgesia 
Confluent 
fibrinous 
mucositis/ 
severe pain 
requiring 
narcotic 
Ulceration
, 
haemorrha
ge or 
necrosis 
HEMATO
LOGIC  
WBC-
(X1000 
   >  4.0      4.0 - 3.0     3.0 - 2.0      2.0 - 1.0       <1.0 
PLATELE
TS 
(X 1000) 
>=100 75 - <100 50 - <75 25 - <50 <25 or 
spontaneo
us 
bleeding 
HEMOGL
OBIN 
(GM %) 
>11 11-9.5 <9.5 - 7.5 <7.5 - 5.0 ------- 
Table 7- RTOG acute toxicity criteria 
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COMMON TOXICITY CRITERIA: 
 
 GRADE 0 GRADE 1 GRADE 2 GRADE 3 GRADE 4 
EMESIS none 1 episode in 24 
hours;IVfluids 
indicated in < 
24 hours. 
2-5 
episodes 
in 24hours 
>6 
episodes in 
24 hours; 
IV fluids, 
or TPN 
indicated > 
24 hrs 
 
Life-
threatening 
consequences 
 
Table 8- CTC for emesis 
 
The toxicities during concurrent chemo radiation depends on chemotherapy 
agents used, dose per fraction, fractionation used. Apart from toxicities due to 
individual chemotherapy the other toxicities are graded as per RTOG toxicity 
criteria. The toxicities include 
 
 Dermatitis 
 Mucositis 
 Emesis 
 Neutropenia 
 Anemia 
 Thrombocytopenia 
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I.4.CISPLATIN AND RADIATION: 
 
CISPLATIN  
 
HISTORY: 
 
 In 1845 Michele Peyrone first described the compound named cis-platin 
(Cis-diamminedichlroplatinum(II)  and historically it was called as Peyrone’s 
chloride. Later in 1893 the structure of cisplatin was first synthesized and found as 
a part of coordination theory revolution by the swiss chemist Alfred Werner who 
was also called as father of coordination theory. After decades of obscurity 
cisplatin becomes popular in early 1960 when Barnett Rosenberg (11)from 
Michigan state university discovered the cytostatic effect of cisplatin. Barnett 
began series of experiments when electrolysis of platinum electrodes produces 
platinum salts which inhibit the cell division of bacteria E.coli but cell continues to 
grow upto 300 times the normal length and this made cisplatin to test against 
cancer in mice. It also found that only cis-platin has anticancer effects but not 
trans-platin. Cisplatin enter into clinical trial in 1971 and got FDA approved for 
treatment in testicular and ovarian cancer in 1978. 
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STRUCTURE AND SYNTHESIS: 
 
 The chemical formula for is cis-[Pt(NH3)2(Cl)2]. It is a yellow crystalline 
crystal with molecular weight 300. The synthesis of cisplatin has improved much 
as earlier synthesis contains lot of impurities and rapid synthesis of cisplatin came 
into practice after it is first described by Dhara(12) in 1970. Now majority of 
synthesis is based on Dhara’s synthesis. In this K2(PtCl4) added to KI and 
converted into potassium tetraiodo palatinate. To this NH3 is added and forms 
yellow compound cis-[PtI2(NH3)2] and AgNO3 is added to form precipitated AgI 
and Pt(OH2)2(NH3)2]2. The later compound is treated with excess KCl and 
resulting in final product cisplatin as yellow powder. 
    
DHARA’S SYNTHESIS OF CISPLATIN 
 
 
Fig 8: synthesis of cisplatin. 
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MECHANISM OF ACTION: 
 
 Cisplatin enters blood stream along with saline solution and drug remains 
intact due to high concentration of chloride.  It enters cell by passive diffusion or 
active uptake by copper binding proteins. Inside cell chloride ions concentration is 
low and chloride ligand is replaced by water to form reactive charged species so 
that it cannot move out of the cell. 
 
 
Fig 9: Binding of cisplatin with DNA. 
 
 The resulting [PtCl(H2O)(NH3)2]+ compound allows platinum to bind 
guanine bases of DNA forms [PtCl(guanine-DNA)(NH3)2]+ and cross linking 
occurs when it react guanine causing displacement of chloride ligand. Cisplatin 
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crosslinks with DNA in different ways and cause DNA damage and finally leads to 
apoptosis. 
 
 Cisplatin interacts with proteins which also contribute in cellular mitosis 
although this is not primary mode of mechanism. Cisplatin interacts with RNA in 
similar fashion as with DNA. RNA can be replaced easily and only <10% RNA is 
damaged at lethal dose of cisplatin. 
 
DNA CROSS LINKS 
 
Fig 10- DNA cross links caused by cisplatin 
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RESISTANCE: 
 
 The major mechanism of acquired cisplatin resistance is reduction in 
accumulation of cisplatin inside cancer cells due to barriers across cell membrane. 
The other mechanisms are faster repair of DNA adducts  , increased detoxification 
of drug, inhibition of apoptosis, increased DNA repair enzymes and deficiency of 
MMR enzymes(hMLH1, hMSH2). 
 
ABSORPTION: 
 
 Cisplatin not absorbed orally. Cisplatin absorption when administered 
systemically is rapid and complete after administered intraperitoneally.  
 
DISTRIBUTION: 
 
 Volume of distribution is 0.28L/Kg and distributed widely in body with 
increased uptake in liver, kidneys and intestine. More than 90% are bind to plasma 
proteins.  
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METABOLISM: 
 
 The plasma clearance of platinum occurs rapidly during first four hours 
following intravenous administration and proceeds slowly due to covalent binding 
to serum proteins like albumin, transferring and gamma-globulin. The half life of 
cisplatin is 30 to 100 hours depending on rate of infusion. 
 
EXCRETION: 
 
 Cisplatin is eliminated via urine. After first 2-4 hours of intravenous 
administration about 15-25% of cisplatin rapidly excreted and intact form. In first 
24 hours 20-82% is excreted as protein bound. 
 
TOXICITY: 
 
1. Nephrotoxicity- dose limiting toxicity 
2. Nausea and vomiting 
3. Myelosuppression 
4. Hypomagnesimia and hypocalcemia 
5. Neurotoxicity 
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6. Ototoxicity 
7. Metallic taste of food and loss of appetite 
8. Hypersensititvity reactions 
9. Transient elevation of LFT 
10. Ocular toxicity like optic neuritis and papilledema are rare. 
 
INTERACTION OF CISPLATIN AND RADIATION: 
 
 Cisplatin were given along with radiation therapy since early 1970’s. The 
first published paper work based on radiobiological aspects was by Wodinsky et al 
in 1974 where there is increased survival in mice when treated with combined 
cisplatin and radiation. In 1976 Richmond et al and powers demonstrated increased 
DNA damage in bacterial spores and E.coli when cisplatin concurrent with 
radiation is given and found cisplatin as a radio sensitizer.  Cisplatin mediated 
radiation sensitization mechanism were summarized by Wilson et al. Both cisplatin 
and ionizing radiation has common target DNA. Radiation acts on DNA and cause 
potentially lethal damage and lethal damage. Cisplatin inhibit the repair of 
potentially lethal damage caused by radiation through free electron scavenging 
capacity and cause cell kill through additive mechanism.  Radiation produces free 
radicals which produces toxic platinum intermediates and finally resulted in cell 
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killing. Radiation therapy also causes increased cellular uptake of cisplatin. All 
these interaction leads to increased cell cycle arrest and apoptosis. Douple and 
Richmond explore the optimal sequencing of cisplatin and radiation through their 
work in mouse mammary tumor model. They found that tumor regression was 
increased when cisplatin was given one hour before radiation compared to other 
sequence. 
 
Cisplatin enhances the effect of radiation on cell kill when given 
concurrently through several mechanisms: 
 
1. Increased formation of toxic platinum intermediates in the presence of 
radiation induced free radicals 
2. Inhibition of DNA repair 
3. Radiation induced increase in uptake of cisplatin intracellularly 
4. Cell cycle arrest 
 
Radiosensitization of cisplatin is important in the treatment of hypoxic cell 
fraction. If hypoxic cells are treated by radiation alone there is lack or inadequate 
formation of free radicals which causes sublethal damage and potentially damage. 
When cisplatin is given concurrent with radiation in inhibits the recovery of the 
hypoxic cells from the sublethal damage which cause radiosensitization and 
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increasing cell kill. The formation of toxic cisplatin products in the presence of 
radiation also targets intracellular and extracellular sites in radiation field. It also 
addresses systemic disease if adequate dose is given.  
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I.5.BLEOMYCIN AND RADIATION: 
 
BLEOMYCIN: 
 
HISTORY:  
 
 The Japanese scientist Hamao Umezawa(2) and his coworkers during their 
study of water soluble antibiotics found kanamycin, alboverticillin and 
phleomycin. Phleomycin is the first copper containing antibiotic found in nature 
and was unique in its blue color. In 1956 after few years of phleomycin discovery, 
it was found to inhibit Ehrlich carcinoma with a high therapeutic index and to 
inhibit DNA synthesis. As it showed irreversible nephrotoxicity in dog, it was not 
tested clinically. After searching for phleomycin containing antibiotic again 
Umezawa and his coworkers discovered bleomycin in 1966. Bleomycin was 
isolated from cultures of streptomyces verticillus. It was similar to phleomycin in 
blue color and copper containing antibiotic but different from phleomycin in 
stability and UV spectrum. Bleomycin is a stable substance and also stable in 
aqueous solution.   
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 Bleomycin did not show any nephrotoxicity like phleomycin but it caused 
reversible hepatotoxicity. Clinical study of bleomycin conducted and Ichikawa et 
al found anticancer effect on squamous cell carcinoma followed by Kimura et al 
and krakoff et al found is effect on malignant lymphoma. Bleomycin was also 
active against ecrlich ascitic and solid tumors as well as sarcoma. After Umezawa 
published his discovery, in 1969 Nippon kayaku launched bleomycin in Japan. It 
got US FDA approval in 1973.    
 
STRUCTURE & SYNTHESIS OF BLEOMYCIN: 
 
 Bleomycin was isolated as a mixture of 13 gylycopeptides from filtrates of 
Fungus streptomyces verticillus. After 12 years of bleomycin was isolated, the 
conclusive structure of bleomycin and the copper complex (10) the natural form 
produced by fermentation were finally determined in 1978. Various bleomycins 
like glycopeptides from streptomyces verticillus differ in terminal carboxy amine 
moiety. Biogenetically all of these amines are methionine, histididne and arginine. 
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Table 9: Tertiary amines of natural bleomycin 
 Apart from natural amine from which bleomycin produced , new bleomycin 
can be produced by culturing streptomyces verticillus in a medium containing 
special amine which is not present in nature. 
 
 
 
Table 10- Unnatural amines well incorporated into terminal amine moiety of 
bleomycin] 
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 In 1982, the first total synthesis of bleomycin was published. On the basis of 
this bleomycin is divided into four distinct domains. 
 
1) Metal binding domain formed by the pyrimidobalmic acid subunit along 
with the adjacent â-hydroxyl  histidine . This domain act as the coordination 
site required for Fe(II) complexation and molecular oxygen activation 
responsible for DNA cleavage. 
2)  Bithiazole domain also called DNA binding domain located at the carboxy 
terminus of bleomycin . This is linked to variety of functionalized side 
chains (BLM A2, BLM B2, BLMA5, BLMA6) which contains either 
inherent inherent posistive charge or a polyamine chain that is positively 
charged in physiological conditions. This structural property allows 
interaction between positively charged bleomycin and the negatively 
charged phosphate of nucleic acid thus results in the binding of bithiazole 
domain into the minor groove of DNA and subsequent cleavage. 
 
3) The linker domain-(2S,3S,4R)-4amino-3-hydroxy-2-methylpentanoic acid 
subunit provides the connectivity between metal binding domain and 
bithiazole domain and its length correlates with efficacy of DNA cleavage 
by bleomycin. 
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4) The carbohydrate domain is essential for full activity of bleomycin. It is also 
 likely to participate in cell recognition by bleomycin and in cellular uptake. 
 
BLEOMYCIN- THE FOUR DOMAINS AND TERMINAL AMINE MOIETY 
 
 
 
MECHANISM OF ACTION OF BLEOMYCIN: 
 
 Bleomycin(6) inhibits eukaryotic and prokaryotic cell proliferation and 
prevents replication of DNA virus. In intact cells it mainly affects DNA synthesis 
and to lesser extent RNA and protein synthesis. It acts preferentially acts on cells 
that are actively dividing cells particularly blocks G2 and M phase of cell cycle.   
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INTERACTION OF BLEOMYCIN WITH DNA: 
 
Bleomycin has dual properties of binding to DNA and chelating various 
metal ions, particularly iron and copper. Bleomycin-mediated DNA degradation 
requires the presence of a redox-active metal ion such as Fe2+ or Cu+, as well as 
molecular oxygen. Bleomycin binds through metal binding domain with Fe2+ 
derived from hemoglobin or Cu2+ from plasma. It forms a complex with a 
molecule of oxygen to form bleomycin-Fe2+-O2 and when mixed with DNA an 
activated complex containing dioxygen and two molecules of DNA bound iron-
bleomycin is formed. During activation, the reduced Fe2+ oxidized to Fe3+ and 
results in the production of free radicals that cause DNA strand breakage. In 
overall reaction bleomycin acts as ferrous oxidase which catalyses oxidization of 
Fe2+ to Fe3+ and reduction of oxygen. Fe2+ bleomycin can be regenerated from 
Fe3+ bleomycin by an NADH dependent system present in the nucleus. This redox 
recycling resulted in increased DNA damage.  
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Figure 11- Mechanism of action of bleomycin 
 
The activated drug bleomycin-Fe3+-O2 can intercalate with DNA to 
produce atleast four types of DNA lesions.  The extent of DNA lesion depends 
upon the oxygen content of the cell. In the absence of oxygen bleomycin abstracts 
a hydrogen atom from deoxyribose at C4’ position and moves it to guanine. This 
converts deoxyribose to an unstable sugar compound to form a mutagenic lesion, 
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purinic/ apyridiminic (AP) site, where the DNA strand intact but it lacks a base.
 
 
Fig 12-Formation of activated bleomycin and cleavage of DNA 
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In the presence of oxygen, bleomycin can damage sugar moiety which 
results in lack of template formation by DNA polymerase and bleomycin induced 
single strand breaks occurs at 3’end with a fragment of sugar. This latter lesion 3’-
phosphoglycolate to be removed in order to promote cell division as it blocks DNA 
repair synthesis. 
 
  The remaining portion of the fragmented sugar exists in the free base 
propenal form and form base adducts when it reacts with DNA. For example, the 
base propenal bears a malondialdehyde moiety, reacts with guanine to form adduct 
pyrimidopurinone of deoxyguanosine. Bleomycin-Fe2+-O2 complex creates an AP 
site on one strand and a directly opposed single strand break on the complementary 
strand which produces bi- stranded DNA lesions at certain sequences like CGCC. 
The bi-stranded lesions converted into double stranded break when there is 
spontaneous cleavage of the AP site by primary amines.  
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Fig 13-Products of bleomycin induced double stranded DNA cleavage 
 
DNA cleavage by bleomycin is sequence selective fashion at a subset of 
5’GC3’ and 5’GT3’ sites. Bleomycin mediated DNA cleavage has two primary 
pathways 
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1) Frank strand scission, which produces base propenals and results directly in 
DNA cleavage. 
2) Via modified nucleotides that result in alkali labile lesions and subsequent  
cleavage sites in the presence of a base. 
 
INTERACTION OF BLEOMYCIN WITH DNA 
 
 
Fig 13-Interaction of bleomycin with DNA 
 
OTHER BLEOMYCIN INDUCED CELLULAR DAMAGE: 
 
In addition to DNA cleavage bleomycin complex cleaves varieties of RNA. 
By oxidation bleomycin cleaves mRNA, rRNA and tRNA. Bleomycin causes 
release of reactive oxygen species and cause cell and nuclear membrane 
peroxidation, lipid peroxidation, altered intracellular prostaglandin metabolism and 
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carbohydrate oxidation. This also contributes to cell death and damage but this 
effect can be inhibited by antioxidants.  
 
RESISTANCE: 
 
Several mechanisms of resistance to bleomycin have been described. Factors 
include increased drug inactivation, decreased drug accumulation, increased DNA 
repair and to lesser extent hypoxia. The major mechanism of resistance to 
bleomycin is due to bleomycin hydrolase, an aminopeptidase converts bleomycin 
into inactive form by replacing terminal amine of bleomycin with hydroxyl which 
is essential for iron binding and cytotoxic activity. The low levels of bleomycin 
hydrolase in lungs and skin explains increased toxicity of bleomycin in these 
organs. The normal tissue with high level this enzymes such as liver, bone marrow 
and spleen exhibit less susceptibility of bleomycin toxicity. 
 
PHARMACOKINETICS: 
 
ABSORPTION: 
 
Bleomycin is well absorbed when administered parenterally as it is poorly 
absorbed across GI tract. Following are the parental routes of administration that 
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include intramuscular, intravenous, subcutaneous, intrapleural, intraperitoneal and 
attain peak plasma concentration in 30 to 60 minutes.  
 
Routes of administration Bioavailability 
Oral 5% 
Intravenous 100% 
Intramuscular 100% 
Subcutaneous 70% 
Intraperitoneal 45% 
Intrapleural 45% 
 
Table11- Routes of administration of bleomycin and its bioavailability 
 
Serum peak plasma concentration after administration of 15,000IU 
bleomycin following intramuscular and intravenous administration were 1 IU/mL 
and 3.3IU/mL respectively. 
 
DISTRIBUTION: 
 
The mean volume of distribution of bleomycin is 17.5L/m2 or 0.35L/kg. It is 
widely distributed throughout the body with peak concentrations of activated form 
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in skin, lungs, kidneys and bladder and inactivated form in liver and spleen. It does 
not cross the blood brain barrier. In mice high concentration of bleomycin found in 
skin, lung, kidney, lymphatics, peritoneum and tumor if present. The highest 
concentration is found in amniotic fluid, placenta but lesser concentration fetus of 
pregnant mice. 
 
PROTEIN BINDING: 
 
Bleomycin has less than 10 percent of plasma protein binding capacity. 
 
METABOLISM: 
 
Bleomycin undergoes extensive metabolism by cytosolic enzyme cystiene 
proteinase, Bleomycin hydrolase. The enzyme is distributed widely in most tissues.  
 
EXCRETION: 
 
The major route of elimination is through kidneys. With 24 hours 60-70% of 
an administered dose of bleomycin excreted in urine. In patients with normal renal 
function half life is 2-4 hours.  In patients with renal dysfunction excretion of the 
drug is prolonged. For patients with creatinine clearance >35mL/minute the serum 
terminal elimination half life is 115 minutes. For patients with creatinine clearance 
>35mL/min serum terminal half life increases. In patients with renal dysfunction 
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40-50% of dose reduction is recommended. Toxicity is increased in patients with 
renal dysfunction if dose is not reduced. 
 
TOXICITY: 
 
1) The most common side effect of bleomycin is mucocutaneous toxicity. It 
includes mucositis, erythema, striae, rash, hyperpigmentation and 
vesiculation. Less common manifestation of skin includes dermatitis, 
hyperkeratosis, skin peeling and thickening, pruritis and alopecia. Skin 
toxicity correlates with cumulative dose of bleomycin and mostly 
manifest when cumulative dose of 150-200U is reached. 
 
2) Fever and chills occurs in 25-5o% of patients following 2-8hours of drug 
administration and lasts up to 48 hours. 
 
SIDE EFFECTS INCIDENCE 
SKIN TOXICITY 44% 
FEVER AND CHILLS 31% 
NAUSEA AND VOMITING 26% 
STOMATITIS 16% 
ALOPECIA 11% 
PULMONARY TOXICITY 10% 
FATAL PULMONARY TOXICITY 1% 
ANAPHYLACTOID REACTION <1% 
 
Table 11- Incidence of side effects of bleomycin 
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3) Nausea, vomiting and tiredness occur in few patients. 
 
4) The dose limiting toxicity of bleomycin is pulmonary toxicity and occurs 
in 10% of patients. It occurs as interstitial pneumonitis, subacute or 
chronic pneumonitis which progresses into pulmonary fibrosis and 
become fatal in 1% of patient. Routine chest Xray, DLCO should be 
taken to monitor bleomycin therapy. Reduction of 40% value of DLCO 
compared to pretreatment values warranted to stop further bleomycin 
therapy. The early symptom of bleomycin induced pulmonary toxicity is 
dyspnea, cough and low grade fever. Pulmonary function teat shows 
restrictive pattern. Pulmonary toxicity is age and dose dependent. Older 
persons more than 70 years of age and cumulative dose >400U associated 
with increased risk of pulmonary toxicity. 
 
5) Anaphylactic reactions are rare but occurs in <1% of patients with 
lymphoma. It manifests as hypotension, chills, fever, dyspnea. 
Cardiovascular toxicity like raynauds phenomenon, cerebral infarction, 
myocardial infarction rarely reported. 
 
6) Myelosupression is rare. 
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INTERACTION OF BLEOMYCIN AND RADIATION: 
 
Bleomycin was one of the first drugs found to sensitize the effects of 
radiation. As bleomycin is effective against squamous cell carcinoma it is used 
along with radiation therapy as a single agent or along with other chemotherapeutic 
agents. 
 
BLEOMYCIN IN VITRO 
 
In 1972 Matsuzawa et al first report the radiosensitizing effect of bleomycin 
in vitro. There is reduction of the shoulder on radiation survival curve when 
bleomycin is used and indicates that bleomycin may inhibit sublethal damage 
together with direct radiosensitivity. Bleomycin acts as similar fashion as radition 
with increased sensitivity in G2 and M phase so that their interaction is additive. 
But bleomycin has little effect on hypoxic cells. Other studies also confirmed the 
same effect of bleomycin with radiation. 
 
IN VIVO: 
 
In 1972 Juul Jorgenson first demonstrated the interaction of ionizing 
radiation and bleomycin in murine carcinoma in vivo and showed that combination 
of bleomycin and radiation is synergistic when given simultaneously in mouse 
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model. This study leads to the introduction of bleomycin and ionizing radiation 
therapy into clinical trials.  
 
The sensitivity of bleomycin combination with radiation is differed in 
various experimental systems due to varying hypoxic fractions of cells. Effect 
depends upon the sequence and interval between applications of bleomycin and 
radiation suggestive of both direct effect of bleomycin on enhancing radiation and 
additive independent effect of two treatment modalities. 
 
IN NORMAL TISUES:  
 
Interaction of bleomycin and ionizing radiation was tested in several normal 
tissues mostly of ectodermal origin like skin, lip, mucosa, intestines, lung and 
several tissues.  
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When bleomycin and radiation acts on normal skin and lip mucosa there is 
increased in acute skin reaction and also increase in late damage than radiation 
alone. Late damage in the form of fibrosis and skin contracture and indicates 
severe risk of bleomycin and radiation combination. Hematopoietic tissue is not 
affected by bleomycin alone and also combined bleomycin radiation treatment. 
There is enhancement of radiation reaction in intestinal crypt cells due to 
interaction between radiation and bleomycin mainly and also due to direct effect of 
bleomycin alone. Bleomycin has direct effect on lung and also enhanced response 
when lung radiation is combined with it.  Enhancement of radiation is increased by 
bleomycin when it gives simultaneously with radiation. If bleomycin is 
administered with long interval from radiation it reduces the radiation response. 
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 Krishnamurthy et al describes that combination of bleomycin and radiation  
Causes 
 
 Revascularisation and reoxygenation of the shrinking tumor when 
combinations were used. 
 
 Barranco and Humphery established that fractionated dose of bleomycin has 
superior killing of tumor cells both in vitro and vivo and hence when 
bleomycin and radiation given in fractionated doses there is increased cell 
killing. 
 
 Bleomycin inhibits the sublethal injury and fractionated bleomycin and 
radiation has increased cell killing. 
 
 Rapidly dividing cells destroyed more compared to slow or undivided cells 
by radiation. Due to synchrony induced by bleomycin at S/G2 and 
synergism by bleomycin + radiation at G2-M phase enhances the cell killing. 
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REVIEW OF LITERATURE 
 
EFFECT OF BLEOMYCIN RADIOTHERAPY COMBINATION IN 
MANAGEMENT OF HEAD AND NECK SQUAMOUS CELL 
CARCINOMA: Cancer volume 48, Issues 5, pages1106-1109, September 1981. 
Pankaj M. Shah et al.(19) 
 
Fifty nine patients with squamous cell carcinoma of head and neck were 
included in the study. Of 59 patients included in the study 23 patients were treated 
with combined bleomycin and radiation therapy and 36 patients were treated with 
radiotherapy alone. Bleomycin were used in the dose of 15mg I.V on alternate days 
upto total dose of 150mg and radiation therapy is given within half an hour of 
bleomycin. Radiation therapy was given to all patients 200cGy per fraction daily 
six days per week upto TD-40-60Gy. Increased mucositis is reportedin bleomycin 
and radiation arm compared to radiation alone arm (82.6% vs 50%). However 
mucositis requiring treatment interruptions in bleomycin combined with radiation 
arm is 21.7 % compared to radiation alone arm 11.1%. Though there is slight 
increase in bleomycin radiation group (65.2%) compared to radiation alone 
arm(58.3%), it is not statistically significant. 
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COMBINED BLEOMYCIN TREATMENT AND RADIATION 
THERAPYIN SQUAMOUS CELL CARCINOMA OF THE HEAD AND 
NECK REGION PARVINEM et al. Acta radiation oncolgica 1985 nov-
dec:24(6): 487-9.(14) 
 
Patient with squamous cell carcinoma of head and neck were included in the 
study. Patients randomized into bleomycin and radiation (25) and radiation alone 
(21). Bleomycin was given in the dose of 7-15mg I.M. 1 hour before radiation 
during first and third week up to total dose of 75mg or 150mg. Cobalt radiation 
therapy is given to both primary and lymph nodes in dose of 200cGy per fraction 
per day and five days in a week. After 30-32 Gy depending upon positive cases 
patients were taken for surgery in both groups. Among the operated patient there is 
significant difference in absence of viable cells in postoperative specimen among 
bleomycin and radiation group. In patients who have clinical complete response 
radiation completed up to 55-60Gy. No difference in toxicity causing treatment 
breaks due to mucositis. No statistically significant differences found in recurrence 
and survival between both groups. 
 
 
67 
 
 
COMBINED USE OF BLEOMYCIN WITH RADIATION IN THE 
TREATMENT OF CANCER CANCER VOLUME 63, 1978, pp 169-78 
M.Abe et al(20) 
 
During 1971-74 from 18 institutions of Kansai district a cooperative study 
was conducted to determine the effect of bleomycin and radiation in treatment of 
oral cavity, esophagus and bronchogenic carcinoma. Of total 189 patients, 67 
patients were oral cavity cancer randomized to bleomycin combination with 
radiation and radiation alone by envelope method. Bleomycin was given in the 
dose of 15mg intravenously twice weekly upto total dose of 90mg over 3 weeks. 
Radiation therapy was given in the dose of 200cGy per fraction per day for five 
days per week upto 30Gy. At the end of 30Gy patient was treated with surgery or 
radiation therapy depending upon participating doctors. Data showed that there is 
significant increased tumor regression and complete response in patients with 
bleomycin and radiation therapy compared to radiation alone. The 18 month 
survival rate for the combined bleomycin radiation group is increased by 20% 
compared to radiation alone.  
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COMBINED THERAPY OF ORAL CANCER BLEOMYCIN AND 
RADIATION: A CLINICAL TRIAL.Clinical radiology 1977 28, 427-
429.V.SHANTA & S.KRISHNAMURTHI  
 
One hundred and fifty seven patients of squamous cell carcinoma of oral 
cavity were randomized into bleomycin plus radiation and radiation alone. Of 157 
patients 87 patients received bleomycin and radiation and 73 patients received 
radiation alone. Bleomycin were given intravenously or intra-arterialy in dose of 
10-15mg twice or three times a week or intramuscularly in dose of 30mg twice a 
week to total dose of 150mg. Cobalt radiotherapy given to the dose of 6 to 7.5Gy 
per week in combined bleomycin radiation group to total dose of 55-60Gy and 
10Gy per week to total dose of 65Gy in radiation alone group. Significant 
favorable response is reported in combined bleomycin radiation arm (77%) 
compared to radiation alone (20.9%).  There is significant increase in five year 
disease free survival in combined bleomycin radiation group (65.5%) against 
radiation alone (23.5%). 
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BLEOMYCIN AND RADIATION THERAPY IN SQUAMOUS CELL 
CARCINOMA OF THE UPPER AERO-DIGESTIVE TRACT: A PHASE III 
CLINICAL TRIAL IJROBP NOV-1985, VOL 11, 1877-86 VERMUND H et 
al. (15) 
 
A prospective randomized and stratified clinical trial conducted in group of 
222 patients with squamous cell carcinoma of the upper aero digestive tract. Paired 
randomization technique is use prospectively to compare radiation therapy alone to 
bleomycin and radiation therapy. Of 222 patients, 65 patients had larynx cancer, 85 
patients had oral cavity cancer, 23 patients had Oropharynx cancer, 12 patients had 
nasopharynx cancer, 19 patients had hypopharynx cancer and 18 patients had 
sinuses cancer. 70% patients had stage III & IV cancer. Only seven percent of the 
patients were below 50 years of age and most of them were elderly. Twenty seven 
percent of the patients were more than 70 years age. 111 patients received radiation 
alone and 111 patients received both bleomycin and radiation. Radiation delivered 
in dose of 200cGy/fraction, five days in a week to TD-70Gy. Bleomycin was given 
in dose of 5mg intramuscularly per day an hour before radiation. Patient who had 
residual disease received interstitial radiation or surgery. Palliative chemotherapy 
is given for late recurrences. The response of tumor and tumor control were similar 
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for radiation alone and combined bleomycin and radiation. Two year and five year 
survival percentages were equal in both groups. 
 
COMBINED RADIATION THERAPY AND 5-FLUROURACIL FOR 
ADVANCED SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY 
AND OROPHARYNX: A RANDOMIZED STUDY. Lo TC et al. 
 
In 1961, 136 patients with oral cavity cancer and oropharyngeal cancer were 
randomized into combined radiotherapy and 5-FU and radiotherapy alone. In 
combined 5-FU and radiotherapy there is increased local control and survival. But 
it is statistically significant in oral cavity cancer only.  
 
META-ANALYSIS OF CHEMOTHERAPY IN HEAD AND NECK 
CANCER(MACH-NC): An update of 93 randomized trial and 17,346 
patients; PIGNON et al 
 
Four categories according to tumour location: oral cavity, oropharynx,  
hypopharynx and larynx.16,192 patients were analysed, with a median follow-up 
of 5.6 years. The benefit of the addition of chemotherapy is consistent in all 
tumour locations, with hazard ratios between 0.87 and 0.88. Magnitude of benefit 
higher for platinum based chemo (0.75) than for other chemo (0.86) [p=0.01].   
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The interaction test between chemotherapy timing and treatment effect was only 
significant for oropharyngeal (p < 0.0001) and laryngeal tumours (p = 0.05). The 
5-year absolute benefits associated with the concomitant chemotherapy are 8.9%,  
8.1%, 5.4% and 4% for oral cavity, oropharynx, larynx and hypopharynx tumours,  
respectively.  
 
  
72 
 
II.1 AIM OF THE STUDY 
 
To compare the acute toxicity, treatment breaks, clinical response and its 
impact on survival between cisplatin and bleomycin versus cisplatin alone 
concurrent with radiation therapy in locally advanced squamous cell carcinoma of 
oral cavity from the Tertiary cancer centre, South India between january 2009 and 
decembeer 2011. 
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II.2.OBJECTIVES OF THE STUDY 
 
PRIMARY OBJECTIVES: 
 
1. To compare the clinical response of primary and regional lymph nodes 
between the patients treated with cisplatin and bleomycin versus cisplatin 
alone concurrent with radiation for locally advanced squamous cell 
carcinoma during the period from January 2009 to December 2011. 
 
2.  To compare the disease free survival and overall survival between the 
patients treated with cisplatin and bleomycin versus cisplatin alone 
concurrent with radiation 
 
SECONDARY OBJECTIVES: 
 
1. Acute toxicity is defined and graded as per RTOG toxicity criteria .Acute 
toxicity of the treatment such as myelosupression, vomiting, 
mucocutaneous toxicity, pneumonitis were compared  between the 
patients treated with cisplatin and bleomycin versus cisplatin alone 
concurrent with radiation. 
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2. Treatment breaks defined as interruptions of radiotherapy treatment of 
more than five days continuously due to side effect of treatment and 
comparison made between two treatment groups and its impact on 
survival rate is analyzed. 
 
3. Detailed analysis on age groups of person affected, cumulative dose of 
cisplatin and its impact on response and survival is compared. 
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II.3.MATERIALS AND METHODS 
 
STUDY DESIGN:  
 
Retrospective analytical study 
 
STUDY SETTING: 
 
Cancer institute is the tertiary cancer speciality centre in world and founded 
by Dr.Muthulakshmi Reddy on June 18, 1984 in Chennai, India. It includes a 423 
bedded hospital, a research centre on oncology, preventive oncology division and 
college of oncological sciences that conducts various courses like post graduate in 
radiation oncology, surgical oncology, medical oncology, psycho oncology, 
medical physics and nursing oncology. Over 50 new patients and 500 follow up 
patients has been daily in cancer institute. 
 
STUDY POPULATION: 
 
Patients with locally advanced oral cavity carcinoma registered in cancer 
institute from 2009 to 2011 treated with concurrent chemo radiation were 
reviewed. The chemotherapy agents used in concurrent chem. Radiation were 
weekly cisplatin, carboplatin, cetuximab, three weekly cisplatin alone and three 
weekly cisplatin along with biweekly bleomycin. Of 515 patients treated with 
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concurrent chemoradiation all the 216 patients treated with three weekly cisplatin 
with or without bleomycin concurrent with radiation were included in the study. 
 
STUDY PERIOD: 
 
January 2009 to December 2011. 
 
SAMPLE SIZE: 216 
 
Total of five hundred and fifteen patients were treated with concurrent 
chemo radiation using different chemotherapeutic agents like cisplatin, carboplatin, 
bleomycin and cetuximab. Of these all 216 patients treated with three weekly 
cisplatin with or without bleomycin were included in the study. Of 216 patients, 
112 patients were treated with cisplatin and bleomycin concurrent with radiation 
and 104 patients were treated with cisplatin alone concurrent with radiation 
therapy. 
 
STUDY TOOL: 
 
Index registry of the year 2009, 2010 and 2011 from tumour registry and 
case details from case record, chemotherapy chart, radiotherapy chart, bed side 
chart and investigations were reviewed to collect data concerning age, sex, habits, 
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comorbids, disease site, TNM stage, radiotherapy dose/fractionation, 
chemotherapy details, toxicity, response, failure rate, survival status for patients 
treated with cisplatin and bleomycin and cisplatin alone concurrent with radiation. 
 
INCLUSION CRITERIA: 
 
1. Pathologically proven squamous cell carcinoma of oral cavity. 
2. Clinical stage T1-2, N1-3 or T3-4, N0-3 including no distant metastasis. 
3. Performance status ECOG 0-2. 
4. Age >18 years 
5. Absolute neutrophil count (ANC) > 1,500 cells/mm3; Platelets > 100,000 
cells/mm3; Hemoglobin > 10.0 g/dl; Note: The use of transfusion or other 
intervention to achieve Hb >8.0 g/dl is acceptable. 
6.  Adequate hepatic function defined as follows:  
 Bilirubin < 2 mg/dl within 2 weeks prior to registration; 
 AST or ALT < 3 x the upper limit of normal within 2 weeks 
prior to registration. 
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7.   Adequate renal function, defined as follows: 
 Serum creatinine < 1.5 mg/dl within 2 weeks prior to registration or 
creatinine clearance (CC) ≥ 50 ml/min within 2 weeks prior to registration 
determined by 24-hour collection or estimated by Cockcroft-Gault formula 
8. Adequate pulmonary function –Baseline PFT/ DLCO  
9. Informed consent 
 
EXCLUSION CRITERIA: 
 
1. Histopathologically other than squamous cell carcinoma. 
2. Cancers of oropharynx, hypopharynx, larynx, nasopharynx and unknown 
primary of cervical lymphadenopathy. 
3. Stage T1-2,N0 
4. Distant metastasis or adenopathy below clavicles. 
5. Previously treated with surgery. 
6. Simultaneous primaries. 
7. Prior invasive malignancy unless disease free for 3 years. 
8. Prior systemic therapy or radiotherapy for the study cancer. 
9. Prior allergic to cisplatin and bleomycin. 
10. Not willing to sign informed consent.  
79 
 
 
PRE TREATMENT ASSESMENT: 
 
1. Complete history 
2. Complete physical examination. 
3. Examination of oral cavity. 
4 .Indirect laryngoscopy, Direct laryngoscopy and pharngoscopy. 
5. Complete blood work up- hemogram, serology, RFT, LFT, electrolytes, 
    creatinine clearance. 
7. Chest X-ray, ECG, Echocardiogram. 
8. US kidneys 
9. Pulmonary function test- DLCO 
10.CT scan of  head and neck in selected case. 
 
TREATMENT PROTOCOL: 
 
Terasima et al in an experimental study of use of bleomycin in mouse 
fibroblastic cells and lymphatic leukemia cells, survival response as a result of 
varying concentrations of bleomycin is reported. Survival response is interpretated 
in a curve by an upward concave curvature, consists of a steep portion as well as a 
more gradual portion and it is due to resistance induced by bleomycin. This 
resistance can be overcome by removal of bleomycin and completely disappeared 
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after four hours. Based on this finding it is considered that administration of 
bleomycin in smaller dose with increased frequency rather than larger dose with 
lesser frequency of same cumulative dose. Takao Ohnuma et al in his study prove 
that weekly twice schedule of bleomycin was tolerated well in patients. Clinically 
there is small difference in effectiveness of combined bleomycin treatment based 
on timing of bleomycin administration combined with radiation. The scheduling of 
administration of bleomycin before or after radiation was not defined clearly. 
Based on previous clinical experiences this modified dose of radiotherapy 
fractionation and bleomycin dose was adopted in our institute to enhance the local 
control in oral cavity cancer.  
 
GROUP A: 
 
Cisplatin is given in dose of 70mg/m2 every three weekly in all patients. 
Bleomycin is given at dose of 10 units twice a week on Tuesday and Thursday till 
completion of radiotherapy. Radiotherapy to primary and nodal regions is given at 
dose of 250cGy/fraction weekly three days on Monday, Wednesday and Friday to 
TD- 60-65Gy. 
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GROUP B: 
 
Cisplatin is given in dose of 70mg/m2 every three weekly in all patients. 
Radiotherapy to primary and nodal regions is given at dose of 200cGy/fraction five 
days a week to TD-60-66Gy. 
 
Radiation therapy: 
 
Conventional treatment protocol: 
 
Patients in the conventional radiotherapy group were treated with 6MV X-
rays from a linear accelerator using 2 opposing lateral photon fields to treat 
primary, upper and middle cervical lymphnodes and one anterior field to treat 
lower neck nodes.  
 
Field setup: 
 
 Superior border:  Skull base. 
 Inferior border: Bottom of hyoid bone and match with lower anterior neck 
field.  
 Anterior border: Mentum  
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 Posterior border: posterior to spinous processes or in the presence of large 
nodal mass aim to cover more posteriorly. 
 
Low anterior neck field: 
 
Superior: Bottom of hyoid bone and match with upper neck lateral fields. 
Inferior:Inferior edge of the clavicular head Lateral: Two thirds of the clavicle or 2 
cm lateral to the adenopathy(which ever more lateral) 
 
 
 
 
Patient was evaluated with hemogram, renal function test, hepatic function 
test, electrolytes before every cycle of three weekly cisplatin. Total WBC count 
 
• CT-Cisplatin 70mg/m2 three 
weekly + Bleomycin 10U twice 
weekly 
• RT -2.5Gy/# , 3 days/week                
TD-60-66Gy 
Group 
A 
 
• CT-Cisplatin 70mg/m2 three 
weekly 
• RT 2Gy/#, 5 days/week                                                             
TD-60-66Gy 
Group 
B 
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was checked twice a week in all patients and in patients with counts less than 4000 
cells per mm3 bleomycin is pended till count improves. Patients with grade III 
neutropenia and febrile neutropenia received growth factor support and antibiotics. 
In combined bleomycin group chest X ray was taken at the end of 30Gy. In 
Patients who had grade III mucositis, the above chemotherapy is pended 
tillmucositis resolves. 
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III.RESULTS 
 
From January 2009 to December 2011        patients were treated for oral 
cavity cancer in our institute. Of these 216 patients were treated with three weekly 
cisplatin with or without bleomycin concurrent with radiation therapy were 
included for the study. 
 
AGE – SEX DISTRIBUTION: 
 
All 216 patients were in age group between 25 to 63 years. The mean and 
median age is 45 years in both groups. 184 were male patients and 32 patients were 
female patients. There are no statistically significant differences were identified in 
age and sex distribution between both groups. 
 
AGE (years) MALE 
n (%) 
FEMALE 
n (%) 
TOTAL 
216(100%) 
25-34 22(12%) 1(2.9%) 23(10.7) 
35-44 68(36.9%) 7(20.5%) 75(34.7) 
45-54 61(33.1%) 20(58.8%) 81(37.5) 
55-64 33(18%) 4(11.8%) 37(17.1) 
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AGE DISTRIBUTION IN BOTH GROUPS 
 
 
SITE – STAGE DISTRIBUTION: 
 
Eighty percent of patients have tongue and cheek cancers. Of 216 patients 89 
patients has anterior two thirds of tongue cancer, 90 patients has cheek cancer, 23 
patients has gingival cancer, 6 patients has lip cancer, 5 patients has floor of mouth 
cancer and 3 patients has hard palate cancer.  Among all patients 62 percent of 
patient has stage IV cancer. Of 216 patients 82 has stage III cancer, 115 has stage 
IV A cancer and 19 has stage IV B cancer.  
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SITE STAGE III STAGE IVA STAGE IVB n (%) 
TONGUE 37 51 1 89(41.2) 
CHEEK 31 43 16 90(41.7) 
GINGIVUM 8 14 1 23(10.7) 
LIP 2 3 1 6(2.7) 
FLOOR OF 
MOUTH 
2 3 - 5(2.3) 
PALATE 2 1 - 3(1.4) 
TOTAL 82(37.9%) 115(53.2%) 19(8.9%) 216 
               
SITE-STAGE DISTRIBUTION IN BOTH GROUPS 
 
 
No significant difference in site wise and stage wise distribution between 
both groups.  
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COMORBIDS: 
 
 
 
 
Of 112 patients treated with cisplatin and bleomycin concurrent with 
radiation 19 patients has associated comorbid condition in the form of diabetes, 
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hypertension and ischemic heart disease. Of 104 patients treated with cisplatin 
alone 16 patients has associated comorbid condition.  
 
HABITS: 
 
Tobacco chewing, smoking and drinking alcohol are major risk factors for 
oral cavity cancers. Of total 216 patients analysed eighty five percent of patients 
have history of tobacco and alcohol abuse. No statistically significant habit 
differences were identified between both groups. 
 
 
 
TYPE OF TOBACCO USE IN CHEWER: 
 
Types of tobacco used were panmasala and tobacco with or without  
betal nut.  
CHEWER SMOKER ALCOHOLIC 
CHEWER+SMOK
ER 
FEMALE 20 2 0 0 
MALE 140 74 51 51 
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TOXICITY: 
 
In combined cisplatin bleomycin group toxicity expected were 
myelosuppresion, emesis, mucositis, electrolyte imbalance, decreased renal 
function test, ototoxicity, pneumonitis and bleomycin induced rash. In cisplatin 
only group the same toxicities except pneumonitis and bleomycin induced rash 
were expected. Of 112 patients treated with combined bleomycin cisplatin and 
radiation group two patients had bleomycin induced skin rash which requires 
discontinuation of further use of bleomycin. Pneumonitis was not reported.  
 
56 
80 
24 
TYPE OF TOBACCO USED IN CHEWER 
PAN MASALA TOBACCO BETAL NUT 
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MYELOSUPRESSION: 
 
As per RTOG toxicity grading criteria myelosupression during treatment 
recorded. Results were comparable in both groups. 
 
 
 
MUCOSITIS: 
 
Increased mucositis was reported in cisplatin bleomycin group compared to 
cisplatin alone with radiation therapy. There in one grade 4 mucositis reported and 
was in cisplatin bleomycin group. 
 
 
 
 
0 20 40 60 80 100 
CDDP+BLM 
CDDP  
CDDP+BLM CDDP  
GRADE 3 0 2 
GRADE 2 17 13 
GRADE 1 10 13 
GRADE 0 85 76 
MYELOSUPRESSION 
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 Of 112 patient in cisplatin bleomycin combined with radiation number of 
grade 3 and grade 4 mucositis was reported in 49 patients (43.8%) compared to 20 
patients(19.2%) in cisplatin alone with radiation group with statistically significant 
value p <0.005. 
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EMESIS: 
 
 
 
In cisplatin bleomycin group 8(7.1%), 9(8%) and 1(0.9%) patients had 
grade1, grade2 and grade3 respectively. In cisplatin alone group 13(12.5%), 
0.00% 20.00% 40.00% 60.00% 
CDDP+BLM 
CDDP  
P value <0.05 
CDDP+BLM CDDP  
Grade 3&4 mucositis 43.80% 19.20% 
Grade 3&4 mucositis 
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CDDP+BLM CDDP  
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grade 2 
grade 3 
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10(9.6%) and (5.8%) patients had grade1, grade2 and grade3 respectively. Though 
slight increase in emesis is reported in cisplatin only group it is not statistically 
significant between them. 
 
TREATMENT BREAKS: 
 
During treatment toxicity can be managed by symptomatic care and 
temporary stopping of radiation and chemotherapy to help in faster healing of 
symptoms. When radiation is pended for more than five days in a week is called as 
treatment break. There is increased in treatment breaks in combined bleomycin and 
cisplatin arm compared to cisplatin alone arm combined with radiation. 
 
 
 
CDDP+BLM 
CDDP  
16(14.3%) 
9(8.7%) 
TREATMENT BREAKS 
TREATMENT BREAKS 
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TREATMENT RESPONSE: 
 
The response to treatment was assessed at 6 weeks after completion of 
concurrent chemo radiation. Complete regression of lesion is taken as complete 
response. Anything less than that is taken as partial response. In cisplatin 
bleomycin group there is increase in complete response 74(66.1%) compared to 
cisplatin alone 59(56.7%) group with p-value =0.06. 
 
The complete response rate in patients who had treatment breaks was 
increased in combined cisplatin and bleomycin group compared to cisplatin alone 
group (64%vs11.1%) 
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FAILURE RATE: 
 
Failure can be local, regional or distant. It can occur at the end of treatment 
or during follow up after complete response to treatment. There is increased in 
local failure in patient received cisplatin alone concurrent with radiation compared 
to cisplatin and bleomycin group (54.8% vs 44.6%) and also increased in regional 
failure also reported in patient received cisplatin alone concurrent with radiation 
compared to cisplatin and bleomycin group (37.4% vs 21.4%). The distant failure 
rate is comparable in both groups. 
 
 
 
 
 
 
  
0 
10 
20 
30 
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SALVAGE SURGERY: 
 
In patients with resectable locoregional failure salvage surgery is considered 
as better option in order to remove cancer that are not responded to initial 
treatment and to improve survival. Of 216 patients treated with concurrent chemo 
radiation 30 patients underwent salvage surgery. In combined cisplatin and 
bleomycin group 20 patients underwent salvage surgery. 26% of patients who had 
local failure and 33.3% of patients who had regional failure are salvaged in 
combined cisplatin and bleomycin group. In cisplatin alone group, of 10 patients 
12.2% and 18.9% of patients who had local and regional failure are salvaged. 
There is statistically significant increase in salvage rate in cisplatin bleomycin 
group compared to cisplatin alone with radiation. 
 
 Total salvage Sx Local failure sal. Regional failure sal. 
CDDP+BLM 20 13/50(26%) 8/24(33.3%) 
CDDP 10 7/57(12.%) 7/37(18.9%) 
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DISEASE FREE SURVIVAL: 
 
The two year disease free survival of combined cisplatin and bleomycin 
group is greater than cisplatin alone with radiation group(45.5% vs 35.5%) with 
statistically significant p-value<0.05.  
 
 
 
Fig- Blue line combined cisplatin+bleomycin+RT; Red line- cisplatin alone + 
RT 
  
98 
 
OVERALL SURVIVAL: 
 
The two year overall survival in combined cisplatin bleomycin group is 
increased compared to cisplatin alone group (60.7% vs 47%) with statistically 
significant p value 0.0043.   
 
 
Fig- Blue line combined cisplatin+bleomycin+RT; Red line- cisplatin alone + 
RT 
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SITE WISE OVER ALL SURVIVAL: 
 
SITE CDDP+BLM CDDP 
CHEEK 26/46(56.5%) 18/44(40.9) 
FLOOR OF MOUTH 2/3(66.6%) 1/2 (50%) 
GINGIVUM 7/11(63.6%) 6/12(50%) 
LIP 1/1(100%) 3/5(60%) 
PALATE 1/1(100%) 2/2(100%) 
TONGUE 31/50(62%) 19/39(48.7%) 
  
STAGE WISE OVERALL SURVIVAL: 
 
STAGE CDDP+BLM CDDP 
III 33/43(76.7%) 28/39(71.8%) 
IVA 31/60(51.6%) 20/55(36.4%) 
IV B 4/9(44.4%) 1/10(10%) 
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TREATMENT BREAKS WISE OVERALL SURVIVAL: 
 
The combined cisplatin and bleomycin group combined with radiation 
causes more treatment breaks compared to cisplatin alone group combined with 
radiation. Increased treatment breaks affects the tumour response and in turn 
survival of the patient. Inspite of increased treatment breaks in combined 
bleomycin cisplatin group compared to cisplatin alone group the two year overall 
survival was increased in combined cisplatin bleomycin group (50% vs 22.2%) 
with statistically insignificant p-value-0.126. In cisplatin alone group even without 
treatment break two year over all survival is 47%. 
 
 
 
Fig- Blue line combined cisplatin+bleomycin+RT; Red line- cisplatin alone + 
RT 
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AGE WISE OVERALL SURVIVAL: 
 
AGE  CDDP+BLM CDDP 
<40 YRS 20/38(52.6%) 10/30(33.3%) 
>40 YRS 46/74(62.2%) 39/74(52.7%) 
 
CUMULATIVE DOSE OF CISPLATIN WISE: 
 
GROUP <200mg/m2 >200mg/m2 
CDDP+BLM 13/25(52%) 55/87(63.2%) 
CDDP 06/15(40%) 43/89(48.3%) 
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IV.DISCUSSION 
 
 The oral cavity cancers are the most common cancer in head and neck 
cancers. Nearly 90 percent of these presents with locally advanced stage. 
Combined modality treatment is usually preferred treatment. When treated with 
only radiation the response to treatment and survival is poor.  This poor response to 
radiation is attributed partly due to large tumors with more necrosis , poor blood 
and oxygen supple and in part due to development of central necrotic core after 
radiation alone as described by Krishnamurthy et al due to centripetal contraction 
of  malignant zone. Surgery improved survival but only twenty five percent accepts 
mutilating surgery and in those patients who underwent surgery after radiation has 
severe cosmesis and functional loss. So from 1960 in our institute various 
combination therapy were tried to improve the response and survival of advanced 
oral cavity cancers. Many well designed, detailed evaluated and randomized study 
were conducted using several agents in our institute by Krishnamurthy et al. 
Radiation therapy was combined with 
 
 Synckavit in 1967 
 Methotrexate in 1976 
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 Bleomycin in 1980 
 Metronidazole in 1981 
 Bleomycin and hyperbaric oxygen in 1983 
 Pepleomycin and radiation in 1987 
 
Among all these randomized well controlled trial bleomycin combination with 
radiotherapy has better local control and survival rates in oral cavity cancers. 
Everywhere in the world cisplatin dominated as a chemotherapy agent for 
combination with radiation in head and neck cancers. In order to improve the local 
control , survival and as already bleomycin proved better combination with 
radiation in our institute three weekly cisplatin was combined with bleomycin and 
radiation therapy in treatment of locally advanced oral cavity cancers. 
 
 The aim of this study was to analyze the acute toxicites, clinical response 
and its impact on survival between combined cisplatin and bleomycin versus 
cisplatin alone concurrent with radiation in locally advanced oral cavity carcinoma 
treated from January 2009 to December 2011 in our institute. Of total 216 patients 
114 patients were treated with combined cisplatin and bleomycin with radiation 
therapy and 104 patients were treated with cisplatin alone with radiation therapy. 
Patient characteristics like age, sex, site, stage, comorbids and associated habits 
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were equally distributed in both groups.  There is no statistically significant 
difference between cisplatin plus bleomycin and cisplatin alone group in terms of 
patient characteristics.   
 
 Based on the clinical experience with different dose level, frequency used 
and its tolerability on patients when used concurrently with radiation bleomycin 
was given 10units twice weekly in our institute along with radiation. The incidence 
of toxicity is found less without compromising tumor control with this schedule. 
This was also supported by clinical study on tolerance to twice weekly dosage by 
Takao Ohnuma et al where use of bleomycin 15 units twice weekly was tolerated 
better. Initially bleomycin was used with conventional fractionation in our institute 
which results in increased mucositis and increased treatment breaks.  Based on our 
clinical experience this modified radiation fractionation is followed in our institute 
to reduce the bleomycin toxicity without compromising local control.   
 
 The side effects reported were emesis, myelosuppression and mucositis in 
both groups. The myelosuppression was comparable in both groups. As bleomycin 
does not cause bone marrow suppression we did not find increased 
myeolosuppression when combined with cisplatin. The emesis reported in both 
groups was not statistically significant though there is slight increased in emesis in 
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cisplatin alone arm. There is increased mucositis in combined bleomycin and 
cisplatin group compared to cisplatin alone. The incidence of grade 3 and grade 4 
mucositis was more in combined bleomycin and cisplatin group compared to 
cisplatin alone (43.8% vs 19%).  The treatment breaks between two groups are not 
statistically significant though there is slight increased in treatment breaks in 
cisplatin and bleomycin group (14% vs 9%).  The increased mucositis with use of 
bleomycin and radiation also reported in Pankaj Shaw et al, Cachin et al and 
Vermund et al where majority are pharyngeal cancers . Pankaj M shaw et al 
reported 80% mucositis in bleomycin group but mucositis causing treatment breaks 
was only 22 percent.  Though there is increased incidence of mucositis there is 
lesser percentage of patients has treatment break in our study this is because all 
patients are oral cavity cancer. All patients has feeding tube to improve nutrition 
and good local care enables to improve mucositis easily compared to other studies 
where majority of patients treated were oropharyngeal cancers where local care is 
difficult compared to oral cavity. Parvinem et al did not report increased mucositis 
in patients treated with bleomycin and radiation.  
 
 There was no pneumonitis or decreased in lung function reported in 
combined bleomycin and cisplatin group. Two patients developed bleomycin 
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induced rash after receiving 30 units of bleomycin. One patient has decreased renal 
function in cisplatin alone group. No other side effects reported in both groups. 
 
 The local control rates in combined cisplatin and bleomycin group was 59 
percent in comparison to 46 percent in cisplatin alone combined with radiation 
group. The increased tumor control was also reported by Krishnamurthy et al, 
Kapstad et al(13) and Abe et al. No difference in tumor control was reported by 
Cachin et al and vermund et al. This difference in tumor control by Vermund et al 
may be because increased number of old age persons in this study. Only seven 
percent of the patients were below the age of 50 years and more than twenty seven 
percent of patients were above seventy years of group. As per MACH NC analysis 
the benefit of chemotherapy in terms of survival was not observed in patients over 
65 years of age. The mean age in cachin et al study was 50 years and only 83 
percent were evaluable at the end of study.  The use of bleomycin with 
conventional fractionation in these study results in increased complication where in 
our institute fractionation was different. 
 
 The local failure in cisplatin plus bleomycin group and cisplatin alone group 
was 44.6% and 54.8% and regional failure was 21.4% and 37.4% respectively. The 
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decrease in local and regional failure was not found in distant failure which is 
comparable in both groups.  
 
 Among the patients who have failed in cisplatin and bleomycin group 26% 
of patients with local failure and 33.3% of patients with regional failure group 
were salvaged successfully. Among the patients with cisplatin alone group 12% of 
patients with local failure and 18.9% of patients with regional failure were 
salvageable.  The increased salvageable rate found in cisplatin bleomycin group. 
 
 The 2 year survival rates in combination cisplatin and bleomycin group was 
significantly better when compared to cisplatin alone group (60.7% vs 47%). The 2 
year survival rate decreases as stage increased.  
 
 The increased survival benefit of cisplatin and bleomycin also seen subsite 
wise. In our study cheek cancer has lesser survival rate compared to other subset 
because there in increased number of patients with stage IV B compared to other 
sites.  
 
 There are studies which shows decreased overall survival in younger 
patients lesser than 40 years of age. Our study also shows decreased over all 
108 
 
survival in younger patients compared to patients in age group in more than 40 
years of age. The cisplatin and bleomycin group shows better survival in younger 
patients in age group less than 40 years of age compared to cisplatin alone group 
(52.6% vs 33.3%).   
 
 It is well known that treatment breaks will affect response of the disease and 
survival of the patients. When the two year survival rate was compared in both 
groups among patients who had treatment breaks the difference in survival was 
statistically insignificant although increased survival was found in cisplatin and 
bleomycin group. 
 
 The effect of cisplatin is increased when cumulative dose of cisplatin was 
more than 200mg/m2. The two year overall survival was better in patients with 
combined cisplatin and bleomycin group who received cumulative dose of 
cisplatin more than 200mg/m2 compared to those treated with cisplatin alone 
group (63.2% vs 48.3%). In patients with cisplatin and bleomycin group who 
received cumulative dose of cisplatin less than 200mg/m2 the two year survival 
was 52% and was lesser than cisplatin alone who received lesser than 
200mg/m2(52% vs 40%) and comparable to the patients who received cumulative 
dose of cisplatin more than 200mg/m2 in cisplatin alone group(52% vs 48.3%) . 
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V.CONCLUSION: 
 
 The present study shows evidence favoring use of bleomycin as an addition 
to cisplatin with radiation in locally advanced oral cavity carcinoma under the 
conditions described. The difference in tumor response, failure rates and survival 
curve indicates that addition of bleomycin with cisplatin at best has effect on 
prognosis of the patients with locally advanced oral cavity cancers. There is no 
serious complicates reported except acceptable and manageable oral mucositis 
inshows increased tumor control and increased survival in locally advanced cancer 
with acceptable toxicity. Hence bleomycin can be added to cisplatin to increase 
tumor control and survival. 
 
 However this is only retrospective study and randomized control study is  
needed to confirm these results.  
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